APOGEN Drug Patent Profile
✉ Email this page to a colleague
When do Apogen patents expire, and when can generic versions of Apogen launch?
Apogen is a drug marketed by King Pharms and is included in one NDA.
The generic ingredient in APOGEN is gentamicin sulfate. There are fifteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the gentamicin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Apogen
A generic version of APOGEN was approved as gentamicin sulfate by SANDOZ on December 31st, 1969.
Summary for APOGEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 34 |
Formulation / Manufacturing: | see details |
DailyMed Link: | APOGEN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for APOGEN
US Patents and Regulatory Information for APOGEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pharms | APOGEN | gentamicin sulfate | INJECTABLE;INJECTION | 062289-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
King Pharms | APOGEN | gentamicin sulfate | INJECTABLE;INJECTION | 062289-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |